- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03101696
Determination of Coronarphysiological Parameters With the Method of Thermodillution
Study Overview
Status
Detailed Description
Fractional flow reserve (FFR), coronary flow reserve (CFR) and the index of microcirculatory resistance (IMR) provide significant information on the conductance of coronary macro- and microcirculation.
FFR-based functional assessment of coronary artery disease has proven to be superior to purely morphologic assessment and thereby guides therapy decision. IMR is a pressure-temperature derived parameter for quantifying microcirculatory resistance, which has been proven to be relatively independent of epicardial stenosis severity when taking collateral flow into account. IMR is increased in patients with acute myocardial infarction and microvascular obstruction (MVO) as assessed by contrast-enhanced CMR and predicts left ventricular function and enddiastolic volumes at 6 month independently of initial infarct size.
Most interestingly, even in the absence of obstructive coronary artery disease, IMR is elevated in more than 20% of patients presenting with chest pain. The clinical meaning for this finding has to be elucidated.
FFR, CFR and IMR can only be measured under conditions of minimal coronary resistance with the need for coronary hyperemia. The current "gold standard" to induce hyperemia in the assessment of coronary conductance is adenosine. However, adenosine is known to cause side effects (bronchospasm and disturbances in atrioventricular conduction) due to its unselective action on all adenosine receptors. Besides that, adenosine requires a body weight adapted dosing and continuous infusion. However, alternative routes like intracoronary injection show good correlation compared with the intravenous route and side effects can be reduced. In contrast, regadenoson, a specific A2A receptor agonist, exhibits negligible side effects. It can be administered intravenously as a non-body weight adapted bolus via peripheral vein without the need for transfemoral delivery. Thus, patients with a transradial access for cardiac catheterization might benefit the most from inducing hypermedia via peripheral vein. It has already been shown that regadenoson increases coronary blood flow yielding comparable values for FFR and indexes of perfusion in SPECT. However, the duration and stability of regadenoson-induced hyperemia might be insufficient for a simultaneous measurement of FFR, CFR and IMR, which has not been tested so far.
The aim of the present study is to evaluate whether simultaneous measurement of the parameters FFR, CFR and IMR under regadenoson-induced hyperemia is feasible, safe and effective in patients with stable coronary artery disease undergoing a transradial procedure
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Dusseldorf, Germany, 40225
- Division of Cardiology, Pulmonary Disease and Vascular Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Coronary angiography with indication of FFR measurement
- angiography without pathological results explaining the patients' symptoms
- intermediate stenosis (50-70%)
Exclusion Criteria:
- <18 years
- Hypersensitivity towards regadenoson
- hemodynamic instability
- severe hypotension
- acute myocardial ischemia
- AV block II-III
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
fractional flow reserve (FFR)
Time Frame: Baseline
|
Description: the proximal aortic (Pa) and distal arterial pressure (Pd) are recorded and RadiAnalyzer Xpress™ control unit automatically calculates FFR as Pd/Pa
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
coronary flow reserve
Time Frame: Baseline
|
The RadiAnalyzer Xpress™ calculates CFR as Tmnr/Tmnh
|
Baseline
|
index of microcirculatory resistance
Time Frame: Baseline
|
Using the derived Pd and transit mean times under hyperemia (Tmnh), it will be calculated apparent IMR as Pd×Tmnh.
All IMR values are also corrected by Yong's formula (IMRcorr=Pa×Tmnh×([1.35×Pd/Pa]-0.32)
to adjust for the influence of collateral flow.
|
Baseline
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-024 (HMR Protocol Code)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Stenosis of Unclear Hemodynamic Relevance
-
Biotronik (Beijing) Medical Device Ltd.Biotronik AGEnrolling by invitationNative Coronary Artery Stenosis | In-Stent Stenosis (Restenosis) of Coronary Artery StentChina
-
Das Radiologische ZentrumHeidelberg UniversityRecruiting
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedCardiovascular Risk Factor | Platelet Aggregation, Spontaneous | Discrete Coronary Artery Stenosis | Coronary Angiography of Multiple DetectorsBrazil
-
Abbott Medical DevicesBristol-Myers Squibb; Eli Lilly and Company; Daiichi Sankyo, Inc.; Baim Institute...CompletedMyocardial Ischemia | Coronary Artery Disease | Coronary Disease | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Vascular Disease | Coronary Artery StenosisUnited States
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Concept Medical Inc.Cardiovascular Research Foundation, New YorkNot yet recruitingCardiovascular Diseases | Coronary Artery Disease | Native Coronary Artery Stenosis
-
Axetis AGUnknownNative Coronary Artery StenosisNetherlands